NDATOPICALCREAM
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OXISTAT (oxiconazole nitrate) by Sandoz is clinical pharmacology pharmacokinetics: the penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. First approved in 1988.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXISTAT (oxiconazole nitrate) is a topical imidazole antifungal cream approved in 1988 that inhibits ergosterol biosynthesis to disrupt fungal cell membrane integrity. It is indicated for treatment of various dermatophyte and yeast infections including tinea pedis, tinea cruris, tinea corporis, and tinea versicolor. The drug demonstrates low systemic absorption with less than 0.3% urinary recovery, concentrating in skin layers where antifungal activity is needed.
$0.251MPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D claims (276 in 2023), indicating a mature, niche market with limited commercial growth opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics: The penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. Five hours after application of 2.5 mg/cm of oxiconazole nitrate cream onto human skin, the concentration of…
Indications
Worked on OXISTAT at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.